The overall goal of the studies described in Project 2 is to improve the outcome of allogeneic marrow transplantation from matched family members in the treatment of lymphoid malignancies, including acute lymphocytic leukemia (ALL), malignant lymphoma and multiple myeloma. In patients with ALL and malignant lymphoma who have not received dose-limiting radiotherapy, the toxicity and efficacy of recombinant alpha interferon given after a preparative regimen of cyclophosphamide and total body irradiation will be evaluated. This study is based on a previous randomized trial which showed that nonrecombinant interferon reduced by 50% the incidence of posttransplant relapse in patients with ALL. In patients with ALL and malignant lymphoma who have received dose-limiting radiotherapy, and attempt will be made to reduce the toxicity of a preparative regimen of carmustine, cyclophosphamide and etoposide with the addition of pentoxifylline. In patients with multiple myeloma the use of marrow transplantation earlier in the course of the disease will be explored and new preparative regimens developed. In """"""""early"""""""" patients, including those with poor risk factors after initial response and those with relapsed disease but a low tumor burden, a trial of busulfan, cyclophosphamide and allogeneic marrow transplantation will be performed. In patients with advanced disease, a new treatment approach which combines biochemically targeted radiotherapy using 186Re-HEDP with a standard busulfan/cyclophosphamide regimen will be evaluated.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-19
Application #
3749234
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
19
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Armenian, Saro H; Yang, Dongyun; Teh, Jennifer Berano et al. (2018) Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv 2:1756-1764
Petersdorf, Effie W; Stevenson, Philip; Malkki, Mari et al. (2018) Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol 36:2524-2531
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580
Lee, Stephanie J; Onstad, Lynn; Chow, Eric J et al. (2018) Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica 103:1535-1541
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515

Showing the most recent 10 out of 1845 publications